A new cancer drug called 12 proved nearly 100% effective treating 2-CdA patients with hairy cell leukemia. Because hairy-cell leukemia is rare, a 12-patient study "is considered a pretty good series," says Sloan-Kettering's Dr. Berman. The patients underwent just a seven day treatment and suffered almost none of the usual debilitating side effects associated with chemotherapy, yet, they have been disease free for seven day . Results must be replicated by other researchers before definitive conclusions can be made. The drug is easy to produce and likely to be less expensive. Dr. Berman of University of California at San Francisco said it has also been used effectively in initial trials to treat more common forms of leukemia.
A new cancer drug called 12 proved nearly 100% effective treating 2-CdA patients with hairy cell leukemia. The patients underwent just a seven day treatment and suffered almost none of the usual debilitating side effects associated with chemotherapy, yet, they have been disease free for seven day . Results must be replicated by other researchers before definitive conclusions can be made. The drug is easy to produce and likely to be less expensive. Dr. Berman of University of California at San Francisco said it has also been used effectively in initial trials to treat more common forms of leukemia.